Shopping Cart
Remove All
Your shopping cart is currently empty
BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC50 = 8 pM). It is selective for EGFR over other tyrosine and serine/threonine kinases, and cellular studies show that BPIQ-II can selectively inhibit EGF-stimulated signal transmission by competitively binding at the ATP site of EGFR.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 500 μg | $330 | 35 days | 35 days | |
| 5 mg | $2,300 | 35 days | 35 days |
| Description | BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC50 = 8 pM). It is selective for EGFR over other tyrosine and serine/threonine kinases, and cellular studies show that BPIQ-II can selectively inhibit EGF-stimulated signal transmission by competitively binding at the ATP site of EGFR. |
| Molecular Weight | 376.64 |
| Formula | C15H11BrClN5 |
| Cas No. | 171179-37-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: 30 mg/mL (79.65 mM), Sonication is recommended. DMSO:PBS (pH 7.2)(1:9): 0.1 mg/mL (0.27 mM), Sonication is recommended. DMF: 10 mg/mL (26.55 mM), Sonication is recommended. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.